Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

ELTX Account Payables

Amounts the company owes suppliers for goods and services received.

Elicio Therapeutics, Inc.NASDAQ: ELTX

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 93.3% from a year ago

Account payables stood at $272K at the end of Q1 FY2026, down 93.3% from a year earlier and down 59.5% from the prior quarter. Over 3 fiscal years it compounded at -37.9% a year.

Context

  • Account payables amounted to 1.2% of total assets at the end of Q1 FY2026, down 13.1 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -93.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$272K-59.5% QoQ
Last fiscal yearDec 2025
$672K-35.3% YoY
Year agoMar 2025
$4.04M-93.3% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-93.3%——
1 year-35.3%——
3-year CAGR-37.9%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
672K USD
Year-over-year change
-35.3%
4-year CAGR
-38.5%

Account Payables vs competitors

How ELTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -93.3% is the lowest of 9, against a peer median of -31.7%.
  • Account payables amounts to 1.2% of total assets for ELTX, versus a peer median of 1.9%.
ELTX Competitors
Account Payables for ELTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MISTMilestone Pharmaceuticals Inc.Mar 2026$10.02M USD+320.4%+35.6%5.2%
CRDFCardiff Oncology, Inc.Mar 2026$5.48M USD+51.0%+60.5%11.1%
MOLNMolecular Partners AGMar 2026CHF 1.92M CHF-19.9%-2.0%2.2%
NKTXNkarta, Inc.Mar 2026$1.59M USD+6.4%+5.9%0.4%
ACTUActuate Therapeutics IncMar 2026$1.2M USD-54.6%-10.6%13.5%
RANIRani Therapeutics Holdings, Inc.Mar 2026$858K USD-43.6%-40.4%1.7%
PEPGPepGen Inc.Mar 2026$622K USD-77.0%-15.5%0.4%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$435K USD-89.3%+0.6%0.3%
ELTXElicio Therapeutics, Inc.Mar 2026$272K USD-93.3%-37.9%1.2%
Peer median (excluding ELTX) —-31.7%-0.7%1.9%

Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents88.76M7.8M12.89M17.62M18.56M
Short-term Investments00000
Net Receivables806K0000
Inventory00000
Other Current Assets379K36K895K1.28M73K
Total Current Assets91.25M10.72M16.35M20.69M19.31M
Property, Plant & Equipment (Net)4.44M8.5M7.28M6.19M5.08M
Goodwill00000
Intangible Assets00000
Long-term Investments723K617K0696K0
Tax Assets00000
Other Non-current Assets106K2.83M3.52M600K1.47M
Total Non-current Assets5.27M11.95M10.8M7.49M6.55M
Total Assets96.51M22.66M27.15M28.18M25.86M
Account Payables4.71M2.81M4.37M1.04M672K
Short-term Debt952K692K0901K0
Tax Payables00000
Deferred Revenue2.3M1.44M01.17M0
Other Current Liabilities2.06M444K2.57M2.31M2.53M
Total Current Liabilities11.3M6.87M9.76M11.52M8.11M
Long-term Debt00020.03M9.41M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities092K11K2.83M2.62M
Total Non-current Liabilities3.71M6.88M6.02M27.97M16.12M
Total Liabilities15.01M13.75M15.77M39.49M24.23M
Common Stock300K3K96K110K178K
Retained Earnings(215.14M)(107.01M)(142.2M)(194.1M)(233.67M)
Accumulated OCI(103K)0(197K)(175K)(127K)
Other Stockholders Equity226.01M0000
Minority Interest00000
Total Equity81.51M8.92M11.37M(11.31M)1.64M
Total Debt4.66M7.48M6.92M26.04M14.51M
Net Debt(84.09M)(316K)(5.98M)8.42M(4.05M)

Elicio Therapeutics, Inc.

NASDAQ:ELTX

Intrinsic Alpha fair value

Locked

Current Price

$2.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.